Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 2/2017

01.06.2017 | short review

Hematopoietic stem cell transplantation: up-date from ASH 2016

verfasst von: MD Georg Hopfinger

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Allogeneic hematopoietic stem cell transplantation (allo HSCT) offers a potentially curative approach for acute myeloid leukemia (AML) with intermediate or adverse risk according to the recently published European Leukemia Network (ELN) guidelines. As outcome might be reduced by graft-versus-host disease (GvHD) or infectious complications, tools for early detection of GvHD are warranted. In contrast, autologous stem cell transplantation (ASCT) represents a relatively safe therapeutic approach. However, further improvement can be observed by the introduction of maintenance therapy after single ASCT, e. g., with lenalidomide or rituximab.
Literatur
1.
Zurück zum Zitat Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016;127(1):62–70. CrossRefPubMed Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016;127(1):62–70. CrossRefPubMed
2.
Zurück zum Zitat Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47. CrossRefPubMedPubMedCentral Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47. CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. 2007;109(9):3658–66. CrossRefPubMed Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. 2007;109(9):3658–66. CrossRefPubMed
4.
Zurück zum Zitat Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301(22):2349–61. CrossRefPubMedPubMedCentral Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301(22):2349–61. CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Jaksch M, Mattsson J. The pathophysiology of acute graft-versus-host disease. Scand J Immunol. 2005;61(5):398–409. CrossRefPubMed Jaksch M, Mattsson J. The pathophysiology of acute graft-versus-host disease. Scand J Immunol. 2005;61(5):398–409. CrossRefPubMed
6.
Zurück zum Zitat Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller H, et al. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol. 2015;2(1):e21–e9. CrossRefPubMedPubMedCentral Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller H, et al. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol. 2015;2(1):e21–e9. CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Hartwell M, Ozbek U, Holler E, Renteria A, Reddy P, Aziz M, et al. An early biomarker algorithm predicts lethal graft-versus-host disease and survival after allogeneic hematopoietic cell transplantation. Blood. 2016;128(22):abstr 509. Hartwell M, Ozbek U, Holler E, Renteria A, Reddy P, Aziz M, et al. An early biomarker algorithm predicts lethal graft-versus-host disease and survival after allogeneic hematopoietic cell transplantation. Blood. 2016;128(22):abstr 509.
8.
Zurück zum Zitat Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29(10):2062–8. PubMedPubMedCentral Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29(10):2062–8. PubMedPubMedCentral
9.
Zurück zum Zitat Miklos D, Cutler S, Arora M, Waller EK, Jagasia M, Pusic I, et al. Multicenter open-label phase 2 study of ibrutinib in chronic graft versus host disease (cGVHD) after failure of corticosteroids. Blood. 2016;128(22):abstr LBA-3. Miklos D, Cutler S, Arora M, Waller EK, Jagasia M, Pusic I, et al. Multicenter open-label phase 2 study of ibrutinib in chronic graft versus host disease (cGVHD) after failure of corticosteroids. Blood. 2016;128(22):abstr LBA-3.
10.
Zurück zum Zitat Versluis J, Hazenberg CL, Passweg JR, van Putten WL, Maertens J, Biemond BJ, et al. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. Lancet Haematol. 2015;2(10):e427–e36. CrossRefPubMed Versluis J, Hazenberg CL, Passweg JR, van Putten WL, Maertens J, Biemond BJ, et al. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. Lancet Haematol. 2015;2(10):e427–e36. CrossRefPubMed
11.
Zurück zum Zitat Bornhauser M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M, et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol. 2012;13(10):1035–44. CrossRefPubMed Bornhauser M, Kienast J, Trenschel R, Burchert A, Hegenbart U, Stadler M, et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol. 2012;13(10):1035–44. CrossRefPubMed
12.
Zurück zum Zitat Scott BLP, Logan B, Wu J, Devine S, Porter DL, Maziarz RT. Results of a phase III randomized, multi-center study of allogeneic stem cell transplantation after high versus reduced intensity conditioning in patients with Myelodysplastic Syndrome (MDS) or acute Myeloid Leukemia (AML): blood and marrow transplant clinical trials network. Blood. 2015;126(23):abstr LBA-8. Scott BLP, Logan B, Wu J, Devine S, Porter DL, Maziarz RT. Results of a phase III randomized, multi-center study of allogeneic stem cell transplantation after high versus reduced intensity conditioning in patients with Myelodysplastic Syndrome (MDS) or acute Myeloid Leukemia (AML): blood and marrow transplant clinical trials network. Blood. 2015;126(23):abstr LBA-8.
13.
Zurück zum Zitat Speziali C, Daly A, Abuhaleeqa M, Nitta J, Mourad J, Seftel M, et al. Fludarabine and Busulfan plus low dose TBI versus cyclophosphamide plus TBI in allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia: equivalent outcomes in a recent, large Canadian multicenter cohort. Blood. 2016;128(22):abstr 663. Speziali C, Daly A, Abuhaleeqa M, Nitta J, Mourad J, Seftel M, et al. Fludarabine and Busulfan plus low dose TBI versus cyclophosphamide plus TBI in allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia: equivalent outcomes in a recent, large Canadian multicenter cohort. Blood. 2016;128(22):abstr 663.
14.
Zurück zum Zitat Emery V, Zuckerman M, Jackson G, Aitken C, Osman H, Pagliuca A, et al. Management of cytomegalovirus infection in haemopoietic stem cell transplantation. Br J Haematol. 2013;162(1):25–39. CrossRefPubMed Emery V, Zuckerman M, Jackson G, Aitken C, Osman H, Pagliuca A, et al. Management of cytomegalovirus infection in haemopoietic stem cell transplantation. Br J Haematol. 2013;162(1):25–39. CrossRefPubMed
15.
Zurück zum Zitat Neuenhahn M, Albrecht J, Odendahl M, Schlott F, Dossinger G, Schiemann M, et al. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after alloHSCT. Leukemia. 2017; doi: 10.​1038/​leu.​2017.​16. PubMed Neuenhahn M, Albrecht J, Odendahl M, Schlott F, Dossinger G, Schiemann M, et al. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after alloHSCT. Leukemia. 2017; doi: 10.​1038/​leu.​2017.​16. PubMed
16.
Zurück zum Zitat Roex MC, Van Balen P, Hageman L, Van Egmond E, Veld S, Hoogstraten C, et al. Prevention of viral infections after T cell depleted allogeneic stem cell transplantation by infusion of multi-antigen specific T cell products. Blood. 2016;128(22):abstr 1228. Roex MC, Van Balen P, Hageman L, Van Egmond E, Veld S, Hoogstraten C, et al. Prevention of viral infections after T cell depleted allogeneic stem cell transplantation by infusion of multi-antigen specific T cell products. Blood. 2016;128(22):abstr 1228.
17.
Zurück zum Zitat Wallhult E, Kenyon M, Liptrott S, Mank A, Ni Chonghaile M, Babic A, et al. Management of veno-occlusive disease: the multidisciplinary approach to care. Eur J Haematol. 2017;98(4):322–9. CrossRefPubMed Wallhult E, Kenyon M, Liptrott S, Mank A, Ni Chonghaile M, Babic A, et al. Management of veno-occlusive disease: the multidisciplinary approach to care. Eur J Haematol. 2017;98(4):322–9. CrossRefPubMed
18.
Zurück zum Zitat Strouse C, Zhan Y, Zhang MJ, DiGilio A, Pasquini MC, Horowitz M, et al. Stratification of allogeneic hematopoietic cell transplant by risk of developing veno-occlusive disease: a model for assigning a risk score. Blood. 2016;128(22):abstr 983. Strouse C, Zhan Y, Zhang MJ, DiGilio A, Pasquini MC, Horowitz M, et al. Stratification of allogeneic hematopoietic cell transplant by risk of developing veno-occlusive disease: a model for assigning a risk score. Blood. 2016;128(22):abstr 983.
19.
Zurück zum Zitat Schuster S, Svoboda J, Nasta S, Porter DE, Chong EA, Landsburg DJ, et al. Sustained remissions following chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas. Blood. 2015;126(23):abstr 183. Schuster S, Svoboda J, Nasta S, Porter DE, Chong EA, Landsburg DJ, et al. Sustained remissions following chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas. Blood. 2015;126(23):abstr 183.
20.
Zurück zum Zitat Neelapu S, Locke FL, Bartlett NL, Lekakis L, Miklos D, Jacobson CA, et al. Kte-C19 (anti-CD19 CAR T cells) induces complete remissions in patients with refractory diffuse large B‑cell Lymphoma (DLBCL): results from the pivotal phase 2 ZUMA-1. Blood. 2016;128(22):abstr LB-A 6. Neelapu S, Locke FL, Bartlett NL, Lekakis L, Miklos D, Jacobson CA, et al. Kte-C19 (anti-CD19 CAR T cells) induces complete remissions in patients with refractory diffuse large B‑cell Lymphoma (DLBCL): results from the pivotal phase 2 ZUMA-1. Blood. 2016;128(22):abstr LB-A 6.
21.
Zurück zum Zitat Chapuis A, Egan D, Bar B, Schmitt TM, McAfee M, Perdicchio M, et al. EBV-specific donor cells transduced to express a high-affinity WT1 TCR can prevent recurrence in post-HCT patients with high-risk AML. Blood. 2016;128(22):abstr 1001. Chapuis A, Egan D, Bar B, Schmitt TM, McAfee M, Perdicchio M, et al. EBV-specific donor cells transduced to express a high-affinity WT1 TCR can prevent recurrence in post-HCT patients with high-risk AML. Blood. 2016;128(22):abstr 1001.
22.
Zurück zum Zitat Stadtmauer M, Pasquini M, Blackwell B, Knust K, Bashey A, Devine S, et al. Comparison of Autologous Hematopoietic Cell Transplant (autoHCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), Tandem Autohct with Len Maintenance (TAM) and Autohct with Len Maintenance (AM) for up-Front Treatment of Patients with Multiple Myeloma (MM): Primary Results from the Randomized Phase III Trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 – StaMINA Trial). Blood. 2016;128(22):abstr LBA-1. Stadtmauer M, Pasquini M, Blackwell B, Knust K, Bashey A, Devine S, et al. Comparison of Autologous Hematopoietic Cell Transplant (autoHCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), Tandem Autohct with Len Maintenance (TAM) and Autohct with Len Maintenance (AM) for up-Front Treatment of Patients with Multiple Myeloma (MM): Primary Results from the Randomized Phase III Trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 – StaMINA Trial). Blood. 2016;128(22):abstr LBA-1.
23.
Zurück zum Zitat Le Gouill SS, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Gyan E, et al. Rituximab maintenance after autologous stem cell transplantation prolongs survival in younger patients with mantle cell lymphoma: final results of the randomized phase 3 Lyma trial of the Lysa/Goelams group. Blood. 2016;128(22):abstr 145. Le Gouill SS, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Gyan E, et al. Rituximab maintenance after autologous stem cell transplantation prolongs survival in younger patients with mantle cell lymphoma: final results of the randomized phase 3 Lyma trial of the Lysa/Goelams group. Blood. 2016;128(22):abstr 145.
24.
Zurück zum Zitat Willasch AM, Salzmann-Manrique E, Krenn T, Duerken M, Faber J, Opper J, et al. Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experience. Bone Marrow Transplant. 2017;52(2):201–8. CrossRefPubMed Willasch AM, Salzmann-Manrique E, Krenn T, Duerken M, Faber J, Opper J, et al. Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experience. Bone Marrow Transplant. 2017;52(2):201–8. CrossRefPubMed
25.
Zurück zum Zitat Yu J, Storer BE, Kushekhar K, Abu ZM, Zhang Q, Gafken PR, et al. Biomarker panel for chronic graft-versus-host disease. J Clin Oncol. 2016;34(22):2583–90. CrossRefPubMed Yu J, Storer BE, Kushekhar K, Abu ZM, Zhang Q, Gafken PR, et al. Biomarker panel for chronic graft-versus-host disease. J Clin Oncol. 2016;34(22):2583–90. CrossRefPubMed
Metadaten
Titel
Hematopoietic stem cell transplantation: up-date from ASH 2016
verfasst von
MD Georg Hopfinger
Publikationsdatum
01.06.2017
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2017
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-017-0337-1

Weitere Artikel der Ausgabe 2/2017

memo - Magazine of European Medical Oncology 2/2017 Zur Ausgabe